TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers

Abstract ROS1 tyrosine kinase inhibitors (TKIs) are highly effective in ROS1-positive non-small cell lung cancer, but resistance remains a challenge. We investigated the activity of various TKIs against wildtype and mutant ROS1, focusing on the emerging L2086F resistance mutation. Using Ba/F3 and NI...

Descripció completa

Dades bibliogràfiques

Autors principals:	Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones, Kevin Nusser, Catherine Z. Beach, Guilherme Harada, Alexander Drilon, Monika A. Davare
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2024-08-01
Col·lecció:	npj Precision Oncology
Accés en línia:	https://doi.org/10.1038/s41698-024-00663-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!